Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

The power of proteasome inhibition in multiple myeloma.

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG.

Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14.

PMID:
30427223
2.

A genome-wide Drosophila epithelial tumorigenesis screen identifies Tetraspanin 29Fb as an evolutionarily conserved suppressor of Ras-driven cancer.

Zoranovic T, Manent J, Willoughby L, Matos de Simoes R, La Marca JE, Golenkina S, Cuiping X, Gruber S, Angjeli B, Kanitz EE, Cronin SJF, Neely GG, Wernitznig A, Humbert PO, Simpson KJ, Mitsiades CS, Richardson HE, Penninger JM.

PLoS Genet. 2018 Oct 16;14(10):e1007688. doi: 10.1371/journal.pgen.1007688. eCollection 2018 Oct.

3.

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.

Blood Adv. 2018 Oct 9;2(19):2443-2451. doi: 10.1182/bloodadvances.2018016360.

4.

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.

Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP.

Haematologica. 2018 Jul;103(7):1218-1228. doi: 10.3324/haematol.2017.174482. Epub 2018 Apr 5.

5.

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.

Mahaweni NM, Bos GMJ, Mitsiades CS, Tilanus MGJ, Wieten L.

Cancer Immunol Immunother. 2018 Jun;67(6):861-872. doi: 10.1007/s00262-018-2140-1. Epub 2018 Mar 2.

6.

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.

Br J Haematol. 2017 Dec;179(5):756-771. doi: 10.1111/bjh.14974. Epub 2017 Oct 19.

7.

Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species.

Manent J, Banerjee S, de Matos Simoes R, Zoranovic T, Mitsiades C, Penninger JM, Simpson KJ, Humbert PO, Richardson HE.

Oncogene. 2017 Oct 5;36(40):5658-5660. doi: 10.1038/onc.2017.239.

PMID:
28980625
8.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.

Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M.

Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.

9.

Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species.

Manent J, Banerjee S, de Matos Simoes R, Zoranovic T, Mitsiades C, Penninger JM, Simpson KJ, Humbert PO, Richardson HE.

Oncogene. 2017 Oct 5;36(40):5576-5592. doi: 10.1038/onc.2017.175. Epub 2017 Jun 5. Erratum in: Oncogene. 2017 Oct 5;36(40):5658-5660.

10.

NF-κB dysregulation in multiple myeloma.

Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD, Mitsiades CS.

Semin Cancer Biol. 2016 Aug;39:68-76. doi: 10.1016/j.semcancer.2016.08.005. Epub 2016 Aug 17. Review.

PMID:
27544796
11.

Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.

Mitsiades CS.

Cancer Cell. 2016 May 9;29(5):611-612. doi: 10.1016/j.ccell.2016.04.009.

12.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22.

13.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.

Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.

PMID:
26032514
14.

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD.

Nat Med. 2015 Jun;21(6):572-80. doi: 10.1038/nm.3867. Epub 2015 May 25.

15.

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.

Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM.

Br J Haematol. 2015 Jun;169(6):851-8. doi: 10.1111/bjh.13383. Epub 2015 Apr 1.

16.

Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Mitsiades CS.

J Clin Oncol. 2015 Mar 1;33(7):782-5. doi: 10.1200/JCO.2014.55.5748. Epub 2015 Jan 20. No abstract available.

17.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi: 10.1073/pnas.1421415111. Epub 2014 Dec 8.

18.

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.

Dowling P, Hayes C, Ting KR, Hameed A, Meiller J, Mitsiades C, Anderson KC, Clynes M, Clarke C, Richardson P, O'Gorman P.

BMC Genomics. 2014 Oct 17;15:904. doi: 10.1186/1471-2164-15-904.

19.

Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.

Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD.

Clin Cancer Res. 2014 Nov 1;20(21):5483-95. doi: 10.1158/1078-0432.CCR-14-0902. Epub 2014 Sep 3.

20.

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.

Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS.

Nature. 2014 Jul 31;511(7511):616-20. doi: 10.1038/nature13393. Epub 2014 Jun 22.

21.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.

Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.

22.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.

Weisberg E, Nonami A, Chen Z, Liu F, Zhang J, Sattler M, Nelson E, Cowens K, Christie AL, Mitsiades C, Wong KK, Liu Q, Gray N, Griffin JD.

Leukemia. 2015 Jan;29(1):27-37. doi: 10.1038/leu.2014.149. Epub 2014 May 5.

23.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC.

Blood Cancer J. 2014 Apr 11;4:e202. doi: 10.1038/bcj.2014.23. No abstract available.

24.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC.

Blood Cancer J. 2014 Feb 21;4:e182. doi: 10.1038/bcj.2014.1.

25.

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.

ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub 2014 Mar 17.

26.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.

Blood. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15.

27.

Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.

Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC.

J Clin Invest. 2014 Feb;124(2):644-55. doi: 10.1172/JCI65093. Epub 2014 Jan 9.

28.

Future agents and treatment directions in multiple myeloma.

Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC.

Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18. Review.

29.

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr.

Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.

30.

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.

Hu Y, Zheng M, Gali R, Tian Z, Topal Görgün G, Munshi NC, Mitsiades CS, Anderson KC.

Blood Cancer J. 2013 Nov 1;3:e156. doi: 10.1038/bcj.2013.53.

31.

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.

Lawasut P, Groen RW, Dhimolea E, Richardson PG, Anderson KC, Mitsiades CS.

Semin Oncol. 2013 Oct;40(5):537-48. doi: 10.1053/j.seminoncol.2013.07.010. Review.

PMID:
24135398
32.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T.

Clin Cancer Res. 2013 Oct 15;19(20):5591-601. doi: 10.1158/1078-0432.CCR-12-3676. Epub 2013 Sep 4.

33.

Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.

Mitsiades CS, Chen-Kiang S.

Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S5-13. doi: 10.1016/j.critrevonc.2013.05.014. Epub 2013 Jun 25. Review.

PMID:
23806982
34.

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P.

Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. doi: 10.1007/s00280-013-2136-7. Epub 2013 Apr 16.

35.

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC.

Leuk Res. 2013 Jul;37(7):829-37. doi: 10.1016/j.leukres.2013.03.006. Epub 2013 Apr 9. Review.

PMID:
23582718
36.

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

McMillin DW, Negri JM, Mitsiades CS.

Nat Rev Drug Discov. 2013 Mar;12(3):217-28. doi: 10.1038/nrd3870. Review.

PMID:
23449307
37.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.

PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21.

38.

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC.

J Immunol. 2013 Feb 1;190(3):1360-71. doi: 10.4049/jimmunol.1200593. Epub 2013 Jan 4.

39.

MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.

Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F.

Br J Haematol. 2013 Mar;160(6):779-84. doi: 10.1111/bjh.12175. Epub 2012 Dec 18.

40.

High-throughput approaches to discover novel immunomodulatory agents for cancer.

McMillin DW, Mitsiades CS.

Oncoimmunology. 2012 Nov 1;1(8):1406-1408.

41.

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.

Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P.

Br J Haematol. 2013 Feb;160(3):351-8. doi: 10.1111/bjh.12152. Epub 2012 Dec 13.

42.

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.

Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.

J Breast Cancer. 2012 Sep;15(3):273-82. doi: 10.4048/jbc.2012.15.3.273. Epub 2012 Sep 28.

43.

New proteasome inhibitors in myeloma.

Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG.

Curr Hematol Malig Rep. 2012 Dec;7(4):258-66. doi: 10.1007/s11899-012-0141-2. Review.

PMID:
23065395
44.

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.

Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS.

Br J Haematol. 2012 Nov;159(3):340-51. doi: 10.1111/j.1365-2141.2012.09253.x. Epub 2012 Sep 13.

45.

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.

Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14.

46.

H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.

Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U.

Cancer Cell. 2012 Aug 14;22(2):194-208. doi: 10.1016/j.ccr.2012.06.027.

47.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC.

Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20.

48.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Aug 9;120(6):1290-8. doi: 10.1182/blood-2012-01-404699. Epub 2012 Jun 21.

49.

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Jul 12;120(2):386-94. doi: 10.1182/blood-2011-12-399667. Epub 2012 May 24.

50.

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC.

Br J Haematol. 2012 Jun;157(6):718-31. doi: 10.1111/j.1365-2141.2012.09120.x. Epub 2012 Apr 26.

Supplemental Content

Loading ...
Support Center